NASDAQ:DMPI - DelMar Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.4139 -0.04 (-8.81 %) (As of 12/17/2018 12:13 PM ET)Previous Close$0.4501Today's Range$0.4129 - $0.464452-Week Range$0.33 - $1.82Volume63,986 shsAverage Volume115,615 shsMarket Capitalization$10.15 millionP/E Ratio-0.77Dividend YieldN/ABeta1.76 ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China; and Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed patients with GBM. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Vancouver, Canada. Receive DMPI News and Ratings via Email Sign-up to receive the latest news and ratings for DMPI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DMPI Previous Symbol CUSIPN/A Webwww.delmarpharma.com Phone604-629-5989 Debt Debt-to-Equity RatioN/A Current Ratio4.41 Quick Ratio4.41 Price-To-Earnings Trailing P/E Ratio-0.77 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-8.28 Profitability EPS (Most Recent Fiscal Year)($0.54) Net Income$-11,130,000.00 Net MarginsN/A Return on Equity-3,999.24% Return on Assets-124.64% Miscellaneous Employees4 Outstanding Shares22,560,000Market Cap$10.15 million OptionableNot Optionable DelMar Pharmaceuticals (NASDAQ:DMPI) Frequently Asked Questions What is DelMar Pharmaceuticals' stock symbol? DelMar Pharmaceuticals trades on the NASDAQ under the ticker symbol "DMPI." When did DelMar Pharmaceuticals' stock split? How did DelMar Pharmaceuticals' stock split work? Shares of DelMar Pharmaceuticals reverse split on Friday, May 20th 2016. The 1-4 reverse split was announced on Thursday, May 19th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 19th 2016. An investor that had 100 shares of DelMar Pharmaceuticals stock prior to the reverse split would have 25 shares after the split. How were DelMar Pharmaceuticals' earnings last quarter? DelMar Pharmaceuticals Inc (NASDAQ:DMPI) posted its earnings results on Tuesday, November, 13th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01. View DelMar Pharmaceuticals' Earnings History. When is DelMar Pharmaceuticals' next earnings date? DelMar Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 13th 2019. View Earnings Estimates for DelMar Pharmaceuticals. What price target have analysts set for DMPI? 1 Wall Street analysts have issued 1 year price objectives for DelMar Pharmaceuticals' stock. Their predictions range from $12.00 to $12.00. On average, they expect DelMar Pharmaceuticals' stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 2,799.3% from the stock's current price. View Analyst Price Targets for DelMar Pharmaceuticals. What is the consensus analysts' recommendation for DelMar Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DelMar Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DelMar Pharmaceuticals. Has DelMar Pharmaceuticals been receiving favorable news coverage? Media stories about DMPI stock have trended somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. DelMar Pharmaceuticals earned a news impact score of 1.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. Who are some of DelMar Pharmaceuticals' key competitors? Some companies that are related to DelMar Pharmaceuticals include Vascular Biogenics (VBLT), Clearside Biomedical (CLSD), GT Biopharma (GTBP), Celsion (CLSN), Helix Biopharma (HBPCF), ProPhase Labs (PRPH), Addex Therapeutics (ADDXF), Oncolytics Biotech (ONCY), Eyenovia (EYEN), Moleculin Biotech (MBRX), X T L Biopharmaceuticals (XTLB), PLx Pharma (PLXP), Novan (NOVN), Relmada Therapeutics (RLMD) and Neurotrope (NTRP). Who are DelMar Pharmaceuticals' key executives? DelMar Pharmaceuticals' management team includes the folowing people: Mr. Saiid Zarrabian B.Sc., MBA, Pres, CEO & Director (Age 65)Mr. Jeffrey A. Bacha, Founder (Age 50)Dr. Dennis M. Brown, Co-Founder & Chief Scientific Officer (Age 67)Mr. Scott Praill CA, CPA, BSc, CFO & Sec. (Age 51)Dr. Victor Levin M.D., Advisor How do I buy shares of DelMar Pharmaceuticals? Shares of DMPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is DelMar Pharmaceuticals' stock price today? One share of DMPI stock can currently be purchased for approximately $0.4139. How big of a company is DelMar Pharmaceuticals? DelMar Pharmaceuticals has a market capitalization of $10.15 million. The company earns $-11,130,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. DelMar Pharmaceuticals employs 4 workers across the globe. What is DelMar Pharmaceuticals' official website? The official website for DelMar Pharmaceuticals is http://www.delmarpharma.com. How can I contact DelMar Pharmaceuticals? DelMar Pharmaceuticals' mailing address is SUITE 720-999 WEST BROADWAY, VANCOUVER A1, V5Z 1K5. The company can be reached via phone at 604-629-5989 or via email at [email protected] MarketBeat Community Rating for DelMar Pharmaceuticals (NASDAQ DMPI)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 150 (Vote Outperform)Underperform Votes: 135 (Vote Underperform)Total Votes: 285MarketBeat's community ratings are surveys of what our community members think about DelMar Pharmaceuticals and other stocks. Vote "Outperform" if you believe DMPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DMPI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/17/2018 by MarketBeat.com StaffFeatured Article: What is Cost of Debt?